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Abstract

Background and Objectives
Identifying patients who may develop acute kidney injury (AKI) remains
challenging as clinical determinants explain only a portion of individual risk.
Another factor that likely affects risk is intrinsic genetic variability. Therefore,
we performed a systematic review of studies that related the development or
prognosis of AKI to genetic variation.

Design
We searched MEDLINE, EMBASE, HuGEnet, SCOPUS and Web of Science for
articles from 1950 to Dec 2007. Two independent researchers screened articles
using predetermined criteria. Studies were assessed for methodological quality
via an aggregate scoring system.

Results
The 16 included studies were of cohort or case-cohort design, and investigated 35
polymorphisms in 21 genes in association with AKI. Fifteen gene-gene
interactions were also investigated in 4 separate studies. Study populations were
primarily premature infants or adults who were critically ill or post-cardiac
bypass. Among the studies, 5 different definitions of AKI were used. Only 1

polymorphism, APO E e2/e3/e4, had greater than one study showing a significant
impact (p<0.05) on AKI incidence while of gene-gene interactions, this was true
only with the IL-6 -174G/C and TNF- -308G/A combination . The mean quality
score of 5.8/10 (range 4-9), heterogeneity in the studies and the dearth of studies
precluded additional meta-analysis of the results.

Conclusions
Current association studies are unable to provide definitive evidence linking
genetic variation to AKI. Future success will require a narrow consensus
definition of AKI, rigorous epidemiologic techniques and a shift from a priori
hypothesis-driven to genome-wide association studies.

Keywords:
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Introduction

Acute kidney injury (AKI) is a complex disorder manifested by a rapid loss of
renal function that results in retention of metabolic waste products.(1) A disease
that primarily afflicts hospitalized patients, the incidence of AKI has steadily
increased over the past decade, and while mortality has fallen with advances in
renal replacement therapy (RRT), AKI still confers significant morbidity and
mortality.(2-4) Several recent large studies of medical administrative databases
have shown that in-hospital mortality for patients who develop AKI ranges from
20-28%; for those who require RRT, the mortality is higher, ranging from 2833%.(3-5) Currently, there are no effective therapies to treat AKI. The present
standard of care is to remove any potential instigating factors, optimize volume
status and provide supportive care to allow renal function to recover.(1) As
such, the ability to identify high-risk patients and potentially prevent AKI
becomes crucial.

The current literature maintains that a patient’s risk for AKI depends on a
combination of acute insults and chronic co-morbidities. Acute risk factors
include volume depletion, exposure to nephrotoxic agents or drugs such as
aminoglycosides or radiocontrast dye, surgery, and the presence of the systemic
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inflammatory response syndrome or sepsis.(6-9) Chronic risk factors include
advanced age, chronic kidney disease (CKD), diabetes and congestive heart
failure.(9, 10) However, models using these traditional risk factors remain
inadequate.(6, 7, 11-14) Two patients with identical clinical risk factors often react
differently to the same insult; one may suffer no harm while the other may
require RRT. Furthermore, for those who develop RRT-requiring AKI, we as
clinicians remain unable to predict which patients will progress to chronic
dialysis and which will recover kidney function.

Consequently, there are likely to be clinically unobservable risk factors that
contribute to one’s susceptibility to AKI. Our understanding of epithelial,
vascular and immune responses in kidney injury makes it likely that genetic
variability in regulatory elements of these responses plays a major role in
determining one’s risk of AKI, given identical risk factors. This has been seen in
other complex diseases, such as the discovery of a single nucleotide
polymorphism (SNP) in complement factor H as a risk factor for age-related
macular degeneration.(15) While there have not been any animal studies looking
specifically at genetic polymorphisms and their impact on an organism’s
response to AKI, there has been strong evidence for differential gene expression
in the murine model of AKI.(16) A genetic polymorphism that would alter that
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pattern of gene expression would hence change the reaction of an organism or
individual cell to an acute insult, thus making such polymorphisms a plausible
risk factor for AKI.

In AKI, genetic variation in inflammatory cytokines such as Tumor Necrosis
Factor-alpha (TNF-) and Interleukin-6 (IL-6) have recently been proposed as
risk factors.(13, 17-20) This is due to the role of inflammatory mediators in the
pathophysiology of AKI, especially with ischemia and sepsis.(1, 21, 22) Genetic
variations of vasomotor regulatory proteins, such as angiotensin converting
enzyme (ACE) and endothelial nitric oxide synthase (eNOS), have also been
investigated given the importance of vascular reactivity in the pathogenesis of
AKI.(13, 21, 23-25)

However, it remains difficult to ascertain which polymorphisms are truly
associated with AKI.(26) False positive reports are common in genetic
association studies, and the plausibility of an association is highly dependent on
the quality of the studies involved.(27) Therefore, we conducted this systematic
review to evaluate the quality of published studies on genetic associations with
AKI, and to ascertain if the current evidence demonstrates any polymorphism to
be conclusively associated with AKI.

4

Hypothesis and Aims

The primary hypothesis of this study is as follows, that a given patient’s risk of
developing acute kidney injury after a known insult, such as ischemia, sepsis or
nephrotoxic agents, is dependent on that patient’s genetic makeup. That is,
genetic polymorphisms that are commonly found in the population at large will
render a patient either more or less susceptible to AKI. Our aim is to do a
systematic review of the current existing literature on the topic and, where
possible, perform a quality analysis of the studies found in order to determine
the plausibility of the reported associations. Where appropriate, we plan to
perform a meta-analysis to provide pooled odds ratios and relative risks.

Methods

Literature Selection

Studies were selected by searching MEDLINE, EMBASE, HuGEnet, SCOPUS and
Web of Science for articles listed from 1950 up until December 2007. We used
terms such as “acute kidney injury”, “acute renal insufficiency” and “acute renal
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failure” in combination with “genetic variation” and “polymorphism” as our
search criteria. We included many terms in our search to achieve as high
sensitivity as possible.

Search terms were chosen by using keywords found in the Medical Subject
Headings (MeSH) controlled language. This is the search language that is used
by MEDLINE to index all articles found within that database. The MeSH
language tree was searched for any and all keywords or categories associated
with AKI or genetics. Where possible, we excluded more specific terms by
moving up the MeSH language tree in order to use more inclusive search terms.
For example, “genetic polymorphism” was included under “variation
(genetics)”, and “acute tubular necrosis” was included within “acute kidney
failure.” EMBASE search terms were found by matching MeSH terms to their
equivalent EMTREE terms, a different controlled language that is used within
the EMBASE database.

Web of Science, SCOPUS and HuGEnet do not use

controlled languages and therefore a larger number of relevant keywords were
used. Our exact criteria are listed in Table 1 below.
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Table 1 | Search criteria
MEDLINE
Anuria, acute kidney failure, acute renal insufficiency, uremia, oliguria, creatinine, acute
nephropathy or acute kidney injury
AND
Gene frequency, genotype, phenotype, variation (genetics), gene expression, gene expression
regulation, genes or nucleic acid regulatory sequences
EMBASE
Oliguria, creatinine blood level, creatinine, creatinine clearance, anuria, uremia, kidney tubule
necrosis, acute kidney failure, acute kidney tubule necrosis, kidney dysfunction, acute nephropathy
or acute kidney injury
AND
Allelism, genetic heterogeneity, genotype, human genetics, mutation, phenotype, population
genetics, population genetic parameters, gene expression or gene
Web of Science, SCOPUS and HuGEnet
Acute renal insufficiency, acute nephropathy, acute kidney injury, acute tubular necrosis, acute
kidney failure, kidney dysfunction or acute renal failure
AND
Gene frequency, genetic frequency, genotype, phenotype, gene variation, genetic variation, gene
expression, genetic expression, polymorphism, nucleic acid regulatory sequences, allelism,
genetic heterogeneity, mutation or population genetics

A strict set of selection criteria were then applied to the articles found by the
search. We included any original study that pertained to associations between
AKI and human gene polymorphisms or variability. Our exclusion criteria were
the following: 1) Studies with less than 20 subjects; 2) Case reports and series; 3)
Animal studies; 4) Outpatient studies; 5) Studies where the etiology of AKI was
HUS/TTP, ischemia/reperfusion of a kidney allograft, IgA nephropathy or
glomerulonephritis.
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The reasons for each of the exclusion criteria are as follows. For criteria 1), the
effect found in a study with fewer than 20 subjects was as likely to be from
chance as an actual effect, despite achieving statistical significance. Therefore, all
such small studies were excluded. Likewise, case reports and series would likely
have small numbers and also would not be able to show an association, given
that no comparison would have been made to a control group or an at risk
population. Animal studies were excluded because we were interested primarily
in how human genetic heterogeneity contributed to the risk of AKI. Outpatient
studies were excluded as AKI is primarily a disease of hospitalized patients.
Finally, the final criterion was included as we hoped to capture studies of AKI
from ischemia or nephrotoxic injury, which are the commonest causes of AKI in
hospitalized settings.

The titles and abstracts of the articles found by our search were screened using
our selection criteria and articles of interest were selected for full article
evaluation (figure 1); the bibliographies of relevant articles were also searched.
Full articles were then reviewed by two researchers (JL and UP) independently
and a final selection was made; disagreements were discussed and a consensus
decision was reached as to whether or not to include an article. On one article
pertaining to AKI in preeclampsia(28), our discussion was inadequate to achieve
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consensus and a third researcher (CP) evaluated the study, which resulted in its
exclusion.

Data Abstraction

The following data were extracted from each study: first author, journal, year of
publication, number of cases/controls, ethnicity and the clinical setting in which
AKI occurred. The gene polymorphisms or combinations thereof investigated by
each of the studies were recorded, and the conclusions of the authors noted.
Primary and secondary endpoints of each study were recorded as well. Study
quality parameters were also collected. Studies were scored in 10 categories,
which are described in table 2 below. Each study then received an aggregate
quality score using a system adapted from Clark et al.(29) Cohort studies were
automatically given one point in the control group category to facilitate
comparison; this was deemed acceptable as cohort studies are better for studying
high prevalence conditions such as AKI. A study was scored as ‘good’ if the
score was 8-10, ‘fair’ if the score was 5-7 and ‘poor’ if the score was <4.
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Table 2 | Scoring system for study quality used in this systematic review
Quality Criterion
Explanation
Control Group
Was the control group equal or larger than the case group,
and can it be replicated from the description given?
Cohort studies were automatically given a point.
Hardy-Weinberg
Were the case and control groups assessed for HardyEquilibrium
Weinberg Equilibrium?
Can the case group be replicated from the description given,
Case Group
and
was the disease state of interest adequately defined?
Primer
Was the primer sequence used for genotyping or a reference
to one provided?
Can the genotyping method be reproduced from the
Reproducability
description
given, and was the method validated via a second technique?
Blinding
Were the researchers performing the genotyping blinded to
the clinical status of the patient?
Power
Was a power calculation performed?
Calculation
Statistics
Were the major findings presented with well described tests of
tests of significance?
Corrected
If a study examined two or more polymorphisms, were the
statistics corrected for the increased risk of a false-positive
Statistics
finding?
Independent
Was a second, confirmatory study performed?
Replication

Scoring
Yes=1
No=0
Yes=1
No=0
Yes=1
No=0
Yes=1
No=0
Yes=1
No=0
Blinded=1
Not blinded = 0
Yes=1
No=0
Yes=1
No=0
Corrected=1
No correction=0
Yes=1
No=0

Our initial research proposal also included a plan to pool odds ratios and relative
risks for individual genetic polymorphisms in a meta-analysis. Pooling of results
was not undertaken, however, primarily because of marked heterogeneity in
study populations as well as the definition of AKI for studies of specific genetic
polymorphisms.
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Results

Our search returned 7273 unique articles, of which 43 were retrieved for full
article review based upon our screening of titles and abstracts. Reasons for the
exclusion of studies can be found in figure 1. Of those that required full article
review, only 16 articles met our eligibility criteria and were included in the
analysis; initial inter-reviewer agreement on article selection was excellent
(40/43). Overall, these 16 articles investigated 21 candidate genes and 35 separate
polymorphisms in association with AKI. Four studies investigated the role of
gene-gene interactions (i.e. combinations of polymorphisms) describing 15
different combinations and their association with AKI. Of the 21 genes studied, 7
involved inflammatory pathways, 5 with oxidative stress or ischemia, 4 with
vasomotor regulation, 2 with drug metabolism and 1 each involved in
angiogenesis, coagulation regulation and cholesterol metabolism.

Of the 16 included studies, 14 described genetic associations with AKI incidence
(Table 3a) while 2 analyzed AKI outcomes (Table 3b). All studies had a cohort or
case-cohort design; 11 were prospective studies. All study populations were of
mixed gender; 12 studies investigated adults, while 4 studied neonates. Only 9 of
16 studies reported the ethnicity of their populations. The clinical setting where

Table 3a | Characteristics of Studies Examining Genetic Risk Factors for AKI Incidence
Article (author,
year)

Banyasz 2006

Type of study

Retrospective

Site

SC

case cohort
Chew 2000

Prospective

Gene Polymorphism(s) studied

VEGF -2578 C/A, +405 G/C,

# of

# of
AKI

patients

cases

128

Study

Clinical
Setting

Ethnicity

%

Definition of AKI or

Quality

Caucasian

clinical variable studied

Score

41

Population
VLBW
infants

Critically ill

NR

…

Modi 1999†

5

-460 T/C
SC

APO E e2/e3/e4

564

...*

Adults

Post-CPB

NR

…

Delta Cr

7

SC

HSP72 +1267 A/G

120

37

VLBW
infants

Critically ill

Hungarian

100

Modi 1999

5

Caucasian

100

SOFA renal score

9

cohort
Fekete 2003

Retrospective
case cohort

Gordon 2004

Prospective

HSP73 +190 G/C
MC

cohort

TNF-a -238 G/A, -308 G/A

Ethnicity
213

…

Adults

LTA +365 C/G, +249G/A

Critically ill
with sepsis

TNFRSF1A +1135 C/T, +36 A/G,
-609 G/T
TNFRSF1B +1663 A/G, +676 T/G
Guadino 2002

Prospective

SC

IL-6 -174 G/C

111

…

Adults

Post-CPB

NR

…

Delta Cr

6

NR

ACE I/D

248

54

Adults

Post-CPB

NR

…

Bellomo 2004 (RIFLE)‡

4

148

27

Adults

Post-CPB

Chinese,

0

Nash 2002§

4

cohort
Isbir 2007

Prospective
case cohort

APO E e2/e3/e4
AGTR1 +1166 A/C

Luo 2004

Prospective

SC

cohort

Haptoglobin phenotype
(Hp2-2 vs (Hp2-1 and Hp1-1))

Malay
Indian

MacKensen 2004

Prospective

NR

APO E e2/e3/e4

130

…

Adults

Post-CPB

Mixed

NR

Delta Cr

7

SC

ACE I/D

110

42

VLBW
infants

Critically ill

NR

…

Modi 1999

4

cohort
Nobilis 2001

Retrospective
case cohort

AGTR1 +1166 A/C

*Studies that looked at continuous outcome variables did not define cases
† Modi 1999 definition of AKI: serum Cr > 120 umol and/or serum urea > 9 mmol/L, and diuresis of 1.0 mL urine/kg/hr
‡ Bellomo 2004 (RIFLE) definition of AKI: increase in serum creatinine of 50% or greater
§ Nash 2002 definition of AKI: delta Cr > 0.5mg/dL from baseline of 1.9mg/dL or less, 1.0mg/dL from baseline of 2.0 to 4.9mg/dL and 1.5mg/dL for patients with baseline >5.0 mg/dL
Abbreviations: NR= not reported; SC= single centre; MC= multicentre; VLBW = very low birth weight; CPB = cardiopulmonary bypass; Delta Cr = change in serum creatinine in mg/dL

Table 3a continued | Characteristics of Studies Examining Genetic Risk Factors for AKI Incidence
Article (author, year)

Type of study

Site

Gene Polymorphism(s) studied

Stafford-Smith 2005

Prospective

SC

ACE I/D

cohort

# of

# of
AKI

Study

patients

cases

Population

1671

…

Adults

Clinical
Setting

Ethnicity

Post-CPB

Caucasian,

Angiotensinogen +842 T/C

African-

AGTR 1 +1166 A/C

American

%

Definition of AKI or

Quality

Caucasian

clinical variable studied

Score

88

Delta Cr

8

eNOS +894 G/T
IL-6 -174 G/C, -572 G/C, -597 G/A
TNF-a +488 G/A, +376 G/A, -308 G/A
APO E +448 T/C (APOE e4)
APO E +586 C/T (APOE e2)
Sirgo 2004

Prospective

SC

PAI-1 4G/5G

150

11

Adults

Post-CPB

Caucasian

100

Doubling of Cr

4

SC

TNF-a -308 G/A

92

36

VLBW
infants

Critically ill

NR

…

Modi 1999

7

Caucasian

100

# of days free of renal

5

NR

…

cohort
Treszl 2002

Retrospective
case cohort

IL-1b +3954 C/T

with sepsis

IL-6 -174 G/C
IL-10 -1082 G/A
Wattanathum 2005

Prospective

SC

cohort
Woodahl 2007

Retrospective

IL-10 haplotype

158

...*

Adults

121

48

Adults

(-592 C/A, -1082 A/G,+3367 G/A)
SC

cohort

ABCB1 +1236C/T, +2677 G/T/A

Critically ill
with sepsis
Post-HCT

dysfunction
Doubling of Cr

6

%

Definition of AKI or

Quality

Caucasian

clinical variable studied

Score

+3435 C/T,+1199 G/A

*Studies that looked at continuous outcome variables did not define cases
Abbreviations: NR= not reported; SC= single centre; MC= multicentre; VLBW = very low birth weight; HCT = hematopoietic cell transplantation; Cr = creatinine

Table 3b | Characteristics of Studies Examining Genetic Risk Factors for AKI Outcome
Article (author, year)

Perianayagam 2007

Type of study

Prospective

Site

MC

cohort
Jaber 2004

Prospective
cohort

Abbreviations: MC = multicentre

Gene Polymorphism(s) studied

NADPH Oxidase p22phox +242C/T

# of

# of
AKI

Study

Clinical
Setting

patients

cases

Population

200

200

Adults

Hospitalized

Mixed

90

Dialysis or mortality

7

61

61

Adults

Hospitalized

Mixed

93

Mortality and recovery

5

Ethnicity

Catalase -262 C/T
MC

TNF-a -308 G/A
IL-10 -1082 A/G

of renal function
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AKI was studied fell primarily into two groups, post-cardiopulmonary bypass (7
studies) and critically ill with or without sepsis (6 studies). Of the remaining
studies, two investigated all hospitalized patients with AKI, while one study
investigated patients after hematopoietic cell transplant. AKI in all studies was
caused by ischemia/reperfusion, sepsis or nephrotoxic agents.

The definition of AKI varied greatly in the included studies, as no fewer than 5
different definitions of AKI were used.(10, 30, 31) In addition, 4 studies opted to
report only the change in serum creatinine; only the study by Stafford-Smith et
al. stated a reason for doing so, that being the lack of a consensus definition for
AKI at the time of the study. Two studies used hard endpoints of dialysis or
mortality. The quality of studies was generally mediocre; mean quality score
was 5.8/10 (range 4-9). Four studies were scored as ‘poor’, 10 were ‘mediocre’
while only 2 were of ‘good’ quality. Primarily, studies were lacking in the areas
of reproducibility of genotyping methods, blinding, power calculations,
corrected statistics for multiple comparisons and independent replication of
results (Figure 2).(29)

Table 4 describes the specific polymorphisms studied and the authors’
conclusions. In summary, nine polymorphisms (NADPH Oxidase p22phox

Table 4 | Gene characteristics
Gene

Polymorphism

Chromosome

Functional

Type of

significance

polymorphism

Cholesterol metabolism

SNP

Study

Author's conclusion

Comparison

on association

Association

Magnitude of

Significance

Variable

association

of association

with AKI
APO E

NADPH Oxidase

e2/e3/e4

19q13

Isbir 2007

Yes

e4 vs. non-e4

AKI

OR=0.18†

p=0.002

e2/e3/e4

MacKensen 2004

Yes

e4 vs. non-e4

Delta Cr

…

p=0.82

e2/e3/e4

Chew 2000

Yes

e4 vs. e2, e3

Delta Cr

…

p=0.038, p=0.015

e2/e3/e4

Stafford-Smith 2005

No

e4 vs. non-e4

Delta Cr

…

p=0.009*‡

e2/e3/e4

Stafford-Smith 2005

No

e2 vs. non-e2

Delta Cr

…

p=0.32§

+242C/T

16q24

Oxidative stress

SNP

Perianayagam 2007

Yes

CT/TT vs. CC

Dialysis or mortality

OR=2.11

p=0.01

Catalase

-262 C/T

11p13

Oxidative stress

SNP

Perianayagam 2007

No

CT/TT vs. CC

Dialysis or mortality

OR=1.05

p=0.86

ACE

I/D

17q23

Vasomotor regulation

Intron deletion

Isbir 2007

Yes

ID/DD vs. II

AKI

OR=2.37†

p=0.021

I/D

Stafford-Smith 2005

No

II/ID vs. DD

Delta Cr

…

p=0.004*

I/D

Nobilis 2001

No

I vs. D allele

AKI

…

NS

p22phox

AGT

+842 T/C

1q42

Vasomotor regulation

SNP

Stafford-Smith 2005

No

CC/CT vs. TT

Delta Cr

…

p<0.0001*; 0.99||

AGTR1

+1166 A/C

3q21-25

Vasomotor regulation

SNP

Isbir 2007

No

AA vs. AC/CC

AKI

OR=1.09†

p>0.05

+1166 A/C

Stafford-Smith 2005

No

CC/CA vs. AA

Delta Cr

…

p=0.84$

+1166 A/C

Nobilis 2001

No

C vs. A allele

AKI

…

NS

+1166 A/C

Li 2007

No

AA vs. AC/CC

AKI

OR=0.34†

p=0.116

eNOS

+894 G/T

7q36

Vasomotor regulation

SNP

Stafford-Smith 2005

No

TT/TG vs. GG

Delta Cr

…

p=0.17; 0.04*||

ABCB1

+1236 C/T

7q21

Drug metabolism

SNP

Woodahl 2007

No

TT vs. CC/CT

AKI

OR=1.9

p=0.21

+2677 G/T/A

Woodahl 2007

No

TT vs. GG/GT

AKI

OR=1.6

p=0.34

+2677 G/T/A

Woodahl 2007

No

TT vs. TA/GA

AKI

OR=2.5

p=0.33

+3435 C/T

Woodahl 2007

No

TT vs. CT/CC

AKI

OR=1.1

p=0.82

+1199 G/A

Woodahl 2007

No

GG vs. GA/AA

AKI

OR=3.2

p=0.14

*3/*3 vs.

AKI

OR=0.8

p=0.68

CYP3A5

*1/*3

7q21

Drug metabolism

Splice variant

Woodahl 2007

No

HSP72

+1267 A/G

6p21

Ischemia tolerance

SNP

Fekete 2003

Yes

GG vs. GA/AA

AKI

OR=3.17

p<0.01

HSP73

+190 G/C

11q24

Ischemia tolerance

SNP

Fekete 2003

No

G vs. C allele

AKI

…

NS

Haptoglobin

Hp2-2, Hp2-1,

16q22

Fe metabolism,

Phenotype

Luo 2004

Yes

Hp2-2 vs.

AKI

OR=5.4

p=0.03

*1/*3 + *1/*1

or Hp1-1

Anti-oxidant

*Not significant after adjustment for multiple comparisons; †calculated from published data; ‡for caucasian subgroup; §for african american subgroup;
||for caucasian and african american subgroups, respectively
Italics - results from multivariable analysis; NS = not significant

Hp1-1/2-1

Table 4 continued | Gene characteristics
Gene

Polymorphism

Chromosome

Functional

Type of

significance

polymorphism

Proinflammatory

SNP

Study

Author's conclusion

Comparison

on association

Association

Magnitude of

Significance

Variable

association

of association

with AKI
TNF-α

LTA

Jaber 2004

Yes

AA/AG vs. GG

Mortality

HR=2.47

p=0.04

-308 G/A

Stafford-Smith 2005

No

AA/AG vs. GG

Delta Cr

…

p=0.17†

-308 G/A

Gordon 2004

No

A vs. G allele

Renal SOFA score

…

NS

-308 G/A

Treszl 2002

No

A vs. G allele

AKI

…

NS

-238 G/A

Gordon 2004

No

A vs. G allele

Renal SOFA score

…

NS

+376 G/A

Stafford-Smith 2005

No

AA/AG vs. GG

Delta Cr

…

NS

+488 G/A

Stafford-Smith 2005

No

AA/AG vs. GG

Delta Cr

…

NS

Gordon 2004

No

C vs. G allele

Renal SOFA score

…

NS

Gordon 2004

No

G vs. A allele

Renal SOFA score

…

NS

-308 G/A

+365 C/G

6p21

6p21

Proinflammatory

SNP

+249 G/A
IL-1b

+3954 C/T

2q14

Proinflammatory

SNP

Treszl 2002

No

T vs. C allele

AKI

…

NS

IL-6

-174 G/C

7p21

Inflammation modulator

SNP

Stafford-Smith 2005

No

GG vs. CC/CG

Delta Cr

…

NS

-174 G/C

Guadino 2002

Yes

GG vs. CC/CG

Delta Cr

…

p<0.0001

-174 G/C

Treszl 2002

No

C vs. G allele

AKI

…

NS

-572 G/C

Stafford-Smith 2005

No

GG vs. CC/CG

Delta Cr

…

p<0.0001*†

-597 G/A

Stafford-Smith 2005

No

AA/AG vs. GG

Delta Cr

…

NS

Gordon 2004

No

C vs. T allele

Renal SOFA score

…

NS

+36 A/G

Gordon 2004

No

A vs. G allele

Renal SOFA score

…

NS

-609 G/T

Gordon 2004

No

G vs. T allele

Renal SOFA score

…

NS

Gordon 2004

No

A vs. G allele

Renal SOFA score

…

NS

Gordon 2004

No

T vs. G allele

Renal SOFA score

…

NS

Jaber 2004

Yes

GG/GA vs. AA

Mortality

HR=0.36

p=0.03

Treszl 2002

No

G vs. A allele

AKI

…

NS

Banyasz 2006

Yes

AA vs. AC/CC

AKI

OR=0.2

p=0.021

-460 T/C

Banyasz 2006

No

CC vs. CT/TT

AKI

…

NS

+405 G/C

Banyasz 2006

No

CC vs. GC/GG

AKI

…

NS

Sirgo 2004

No

4G/4G vs.

AKI

…

NS

TNFRSF1A

TNFRSF1B

+1135 C/T

+1663 A/G

12p13

1p36

Anti-inflammatory

Anti-inflammatory

SNP

SNP

+676 T/G
IL-10

-1082 G/A

1q31-32

Anti-inflammatory

SNP

-1082 G/A
VEGF

PAI-1

-2578 C/A

-675 4G/5G

6p12

7q21

Angiogenesis

Coagulation activation

SNP

SNP

4G/5G + 5G/5G
*Not significant after adjustment for multiple comparisons; †For caucasian subgroup
Italics - results from multivariable analysis; NS = not significant
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+242C/T; Haptoglobin Hp2-2, 2-1 or 1-1; Heat Shock Protein 72 (HSP72) +1267A/G;
Apolipoprotein E (APO E) e2/e3/e4; Angiotensin Converting Enzyme (ACE) I/D; TNF-

 -308G/A; IL-6 -174G/C; Interleukin-10 (IL-10) -1082G/A; Vascular Endothelial
Growth Factor (VEGF) -2578C/A) were found to have significant associations in
individual studies.(17, 19, 23, 32-36) Only one polymorphism, APO E e2/e3/e4,
had an association with AKI demonstrated in multiple studies.

Cholesterol Metabolism Genes - Apolipoprotein E

Isbir et al.(23) found that in patients undergoing coronary artery bypass grafting
(CABG), carriers of the APO E e4 allele had a decreased risk of AKI compared
with non-APO E e4 patients (unadjusted odds ratio (OR)=0.18, p=0.002). Chew et
al.(33) found the same result in a similar population, as those with the e4 allele
had a smaller postoperative change in creatinine compared to those with e3 and
e2 alleles (p=0.015 vs. e3, p=0.038 vs. e2), even after adjustment for preoperative
creatinine, age, bypass time, hypertension, diabetes and ejection fraction.
Mackensen et al.(37), examining a similar group of 130 CABG patients, also
found this allele to have a protective effect after adjustment for a given amount
of ascending aortic atheroma burden. However, without adjustment no
association was found. Finally, a large study of 1671 cardiac surgical patients by
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Stafford-Smith et al.(13) found no significant association between APO E alleles
and the degree of change of postoperative creatinine in Caucasian or AfricanAmerican populations.

Oxidative Stress Genes

In a study of 200 patients with mixed-cause AKI, Perianayagam et al.(36)
examined the association of polymorphisms in NADPH Oxidase p22phox and
Catalase, two enzymes involved with the regulation of reactive oxygen species,
with dialysis and mortality. Individuals with the T allele in the NADPH Oxidase
p22phox gene possessed a greater risk of dialysis or mortality (unadjusted
OR=2.11). This remained true after adjusting for race, gender, age, APACHE II
score and CKD. No association was demonstrated between the Catalase gene and
AKI. This study was unique in that it is one of two studies that examined
associations with firm outcomes, i.e., dialysis or mortality.(19, 36)

Vasomotor Regulation Genes

For the ACE I/D polymorphism three studies were identified, of which only one
found significant associations with AKI. Isbir et al. found that patients with the
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ACE D allele exhibited increased risk of AKI following CABG (unadjusted
OR=2.37, p=0.021). However, Stafford-Smith and colleagues also examined the
ACE I/D polymorphism and found no association with AKI.(13) Another study
of 110 very low birth weight (VLBW) infants also found no association.(24)

No significant associations were found with other genes involved with
vasomotor regulation, including Angiotensinogen (AGT), Angiotensin Receptor 1
(AGTR1) and eNOS.

Inflammatory and Anti-Inflammatory Genes

Six different studies examined a total of fifteen polymorphisms in seven genes
involved in inflammatory and anti-inflammatory pathways. Jaber et al.(19), in a
study of 61 patients with AKI requiring hemodialysis, found that high producers
of TNF- (-308 A-allele carriers) possessed an increased risk of death after
adjustment for APACHE II score (adjusted hazard ratio (HR)=2.5, p=0.04).
However, three other studies searched for an association between this
polymorphism and AKI incidence, but found none.(13, 18, 20)
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The same study by Jaber et al.(19) also found that IL-10 intermediate/high
producers (-1082 G-allele carriers) had a decreased risk of death after adjustment
for the multiple organ failure score (adjusted HR=0.36, p=0.36). Treszl et al. also
investigated this polymorphism in VLBW infants but found no association with
AKI incidence.(20)

The IL-6 -174G/C polymorphism was investigated in three studies, of which only
Guadino et al.(17) found a significant association. This study found that in
patients undergoing CABG, IL-6 -174GG carriers had significantly higher
elevations in perioperative creatinine vs. non-GG carriers (p<0.0001). However,
Stafford-Smith et al.(13) found no such association in a similar population, nor
did Treszl et al.(20) in VLBW infants.

Other Genes

Luo et al.(35), in a population of 148 CABG patients, found that Haptoglobin 2-2
phenotype was associated with an increased risk of AKI (OR=5.4, p=0.03). In the
HSP72 gene, Fekete et al.(34) found that VLBW infants homozygous for the G
allele were at increased risk for AKI (OR=3.17, p<0.01). This same group also
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found that in the VEGF -2578 C/A polymorphism, VLBW infants homozygous for
the A allele were protected against AKI (OR=0.2, p=0.021).(32)

None of the remaining polymorphisms investigated were found to be
significantly associated with AKI.(38, 39)

Gene-gene Interactions

There were four studies that investigated gene-gene interactions and their
association with AKI. The combinations studied were mostly those that
augmented inflammatory or down-regulated anti-inflammatory pathways (Table
5). Wattanathum et al.(40) found that the CGG haplotype involving three
separate polymorphisms in the IL-10 gene (-592 C/A, +734 A/G and +3367 G/A)
was associated with a greater degree of AKI in patients with sepsis from
pneumonia. They postulated that this genotype is associated with lower antiinflammatory IL-10 production, thus causing increased renal dysfunction.

Jaber et al.(19) investigated whether the combination of pro-inflammatory alleles
from the TNF- -308G/A and IL-10 -1082 G/A polymorphisms, namely the TNF-
-308 AA and IL-10 -1082 AA/AG genotypes, were associated with an increased
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risk for dialysis or death. They found that patients with these genotypes had an
elevated risk for dialysis or death after adjustment for APACHE II score
(adjusted HR=5.17, p=0.005).

Table 5 | Gene combinations
Study

Gene polymorphism

Author's conclusion

Magnitude of

Significance

combinations

on association

association

of association

with AKI
Wattanathum 2005

IL-10 -592 C/A, +734 A/G and +3367 G/A

yes

…

p=0.024

Stafford-Smith 2005

eNOS +894 G/T and AGTR1 +1166 A/C

no

…

p=0.006*‡

IL-6 -572 G/C and TNF-α -308 G/A

yes

…

p=0.05‡

AGT +842 T/C and IL-6 -572 G/C

yes

…

p=<0.0001‡

APO E e4 and AGT +842 T/C

no

…

p=0.03*‡

AGTR1 +1166 A/C and APO E e4

no

…

p=0.02*‡

eNOS +894 G/T and ACE I/D

no

…

p=0.006*§

AGT +842 T/C and APO E e2

no

…

p=0.03*§

Jaber 2004

IL-10 -1082 G/A and TNF-α -308 G/A

yes

HR=5.72

p=0.004

Treszl 2002

TNF-α -308 G/A and IL-6 -174 G/C

yes

OR=6.07†

p<0.01

TNF-α -308 G/A and IL-1b +3954 C/T

no

…

NS

TNF-α -308 G/A and IL-10 -1082 G/A

no

…

NS

IL-1b +3954 C/T and IL-6 -174 G/C

no

…

NS

IL-1b +3954 C/T and IL-10 -1082 G/A

no

…

NS

IL-10 -1082 G/A and IL-6 -174 G/C

no

…

NS

*Not significant after adjustment for multiple comparison; †calculated from published data
‡for caucasian subgroup; §For african-american subgroup
Italics - results of multivariable analysis

Treszl et al.(20) also investigated the TNF- -308G/A polymorphism, but in
combination with the IL-6 -174G/C polymorphism. VLBW infants who had a
combination of the IL-6 -174C allele and the TNF- -308A allele were at increased
risk for developing AKI (OR=6.07, p<0.01). This finding was supported by
Stafford-Smith et al.(13) who investigated the interaction of the IL-6 -572G/C (in
linkage disequilibrium with IL-6 -174C) and TNF- -308G/A polymorphisms and
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found that the combination of IL-6 -572C and TNF- -308A alleles were weakly
associated (p=0.05) with AKI in Caucasians. This study also investigated the
interaction between AGT+842T/C and IL-6 -572G/C polymorphisms, and found
the combination to be significantly associated with AKI (p<0.0001).

Discussion

While there have been several descriptive reviews on this topic,(41-43) to our
knowledge this is the first systematic review of genetic determinants of AKI. In
summary, we found that there is no single polymorphism that can be
conclusively described as a risk factor in AKI. The general dearth of studies, the
lack of confirmatory studies and their overall mediocre quality led us to this
conclusion.

Of the 35 individual polymorphisms whose association with AKI has been
studied, only APO E e2/e3/e4 had a significant association in more than one
study.(23, 33) Apolipoprotein E is an important protein in lipid metabolism. It is
a component of very low density lipoproteins (VLDL) and is the primary ligand
for the LDL receptor in the liver. It has three isoforms, each of which is encoded
by a different allele of the APO E gene, e2, e3 or e4. This gene has been found to
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influence the development of several complex diseases, including Alzheimer’s
disease and atherosclerosis.(44, 45) Recent evidence points to a regulatory role of
APO E in inflammatory responses and may thus be affecting a given patient’s
susceptibility to AKI.(21, 46) However, the positive association found in 3
studies(23, 33, 37) was contradicted by the results from the largest, highest
quality study by Stafford-Smith et al.(13) While it may be the case that the power
of this study to find an effect was diluted by the need to correct for multiple
comparisons, nevertheless its findings cast strong doubt on the positive findings
of the other studies. Furthermore, the study by Mackensen et al only found the
APO e4 allele to be protective after adjusting for ascending aortic atheroma
burden; the association claimed by the authors here is especially weak given that
no relationship was found after adjustment for aortic arch and descending aorta
atheroma burden. Therefore, while a future higher-powered study may find a
role of APO E in AKI, current evidence is inadequate to make such a claim.

Of the gene-gene interactions studied, the combination of the IL-6 -174G/C and
TNF- -308G/A polymorphisms is the most promising, as evidence for an
association has been reported in two separate studies.(13, 20) The association
between the TNF- -308 AA and IL-10 -1082 AA/AG genotypes with dialysis or
mortality demonstrated by Jaber et al., also requires mentioning.(19) While this
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association has yet to be replicated, the individual polymorphisms had small but
significant associations with poor outcomes, and the combined gene-gene
interaction was associated with a much higher risk than either polymorphism
individually, an effect known as multiplicative interaction. This group also
demonstrated phenotypic differences in ex-vivo production of TNF- and IL-10
between genotypic groups, which lends biological plausibility to this linkage.

These results however do not belie the major finding of this review, that thus far
findings in this field have been inconsistent and contradictory. There is
significant inter-study heterogeneity of results, as seen here with APO E and
other polymorphisms, such as TNF- -308G/A and IL-6 -174G/C. Causes for such
heterogeneity include the large number of comparisons performed, which
significantly increases the number of associations found by chance.(47)
Population stratification from ethnic admixture, variable linkage disequilibrium
and population specific gene-gene or gene-environment interactions are also
potential sources of heterogeneity. Therefore, it is recommended for authors to
independently verify their results in an independent sample group prior to
publication.(48) This was an area that was found to be particularly lacking in the
studies included within this systematic review (figure 1). This important
mechanism of quality control is especially necessary given that initial studies
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tend to show more impressive associations then subsequent research, a problem
that is particularly endemic in genetic association research.(27, 49)

Indeed, the problem of false-positive reports has the potential to derail any
potential research in this field before it has truly had a chance to begin. It is for
this reason that evaluating the quality of a genetic association study is critical in
determining whether the association claimed by the authors is indeed true. In
addition to the independent replication of results, other important standards
would include explicit demonstration of genotyping techniques and quality
controls, adequate correction for multiple comparisons and evaluation of
deviations from Hardy-Weinberg equilibrium. Recommendations on study
design and quality control methods for genetic association studies have recently
been published by the NCI-NHGRI Working Group on Replication in
Association Studies.(27) Adherence to these standards will ensure that
associations found in future studies are robust and durable.

Another problem that we have found is one that is somewhat unique to AKI, that
is the lack of a gold standard outcome which has also contributed to study
heterogeneity.(50) We found 5 different definitions of AKI in the studies found
by our search; such variability increases the number of spurious associations and
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makes inter-study comparison difficult. Use of well-defined criteria, such as the
RIFLE (Risk of renal dysfunction, Injury to the kidney, Failure of kidney
function, Loss of kidney function and End-stage kidney disease) or AKIN (Acute
Kidney Injury Network) criteria will decrease heterogeneity and facilitate
comparisons in future investigations.(30, 51) Even in this case however, caution
is advised, in that both the RIFLE and AKIN criteria were formed in order to
maximize sensitivity for AKI. In particular, use of the most sensitive categories
of these classification systems would result in unacceptable dilution of case
groups with false positive subjects. Therefore, we recommend using stage 2 of
the AKIN criteria (a 200% to 300% increase in serum creatinine, or <0.5mL/kg
urine output for 12 hours) as a cutoff, which would allow the creation of case
groups that are both highly specific and have a well-defined phenotype.
Studying outcomes such as dialysis or mortality would also alleviate this
problem; however, due to the rarity of such events, an adequately powered
study examining such outcomes may not be feasible.

Novel biomarkers of kidney injury that are currently under study are another
potential tool to be used in creating a highly specific AKI phenotype. These
biomarkers, unlike creatinine (which is a marker of the glomerular filtration rate,
or GFR), are indicators of cell injury, particular that of tubular cells.(52) The best
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studied of these biomarkers is Neutrophil Gelatinase-associated Lipocalin
(NGAL), which animal studies have shown to be an early marker of ischemic
and nephrotoxic kidney injury.(53) This biomarker has also been shown as a
potential AKI marker in humans that is detectable in both serum and urine.(54,
55) Another marker, interleukin-18 (IL-18), is a mediator of ischemic AKI and
has been studied in multiple clinical scenarios of AKI.(56-58) As evidence
accumulates for the role of these and other novel biomarkers in AKI, they can be
incorporated into existing AKI definitions and be used to further increase case
group specificity.(52, 54)

Our study has limitations in several regards. This systematic review is
vulnerable to several types of bias, the first being publication bias.(59) The
literature has an inherent bias towards the publication of studies that find
positive results.(60) Negative studies may take longer to reach print, if at all.(61)
We made no attempt to retrieve unpublished data, as there is no way to know
whether such efforts would have successfully corrected the bias; indeed,
including such data may even worsen the problem.(59) Therefore, despite using
systematic methods and a highly sensitive search strategy, this may be a nonrepresentative sample of existing genetic association studies of AKI.
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Another potential limitation is analysis reporting bias caused by researchers who
report (or are forced to report due to space limitations) only a portion of their
analyses.(62) This is especially salient in the reporting of gene-gene interactions,
where many combinations of genetic polymorphisms may have been analysed
for association but never reported.

In conclusion, our present understanding of AKI suggests that genetic
heterogeneity in pathways that regulate vascular and inflammatory responses to
injury provide a plausible explanation for individual variability in susceptibility
to AKI. Continued efforts in this field are important, as finding genetic risk
factors will allow us to identify patients at risk and implement preventive
therapies. Identification of culprit genes may also elucidate the true
pathophysiology of AKI. Although some genes show promise, existing
candidate gene studies have been unable to find conclusive evidence to confirm
any association.

An alternative approach will be to use genome-wide association (GWA) studies.
This technique has been harnessed to successfully investigate genetic
vulnerabilities in complex diseases like macular degeneration and diabetes.(15,
63) GWA studies have the advantages of searching for candidate
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polymorphisms unhindered by previous hypotheses and greater power in
demonstrating the effects of gene-gene interactions or high risk haplotypes.(64)
This is especially important for complex disorders, where increased genetic risk
may be from several different polymorphisms acting together. A pitfall is that
GWA studies have unprecedented potential for false-positive results given the
immense number of statistical tests performed; this problem can be somewhat
alleviated by multistage designs and stringent requirements for statistical
significance.(64) Nevertheless, the success of future work will likely depend on
harnessing this revolutionary technique and the application of a true consensus
definition of AKI.
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Figure 2 | Percentage of all studies reviewed that achieved each of the ten quality criteria*
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*Based on Clark MF, Baudouin SV: A systematic review of the quality of genetic association studies in human sepsis. Intensive Care Med
32: 1706-1712. 2006; please see table 2 for full descriptions of each criteria.
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